Emerging Treatment and Prevention Strategies against COVID-19: A Brief Update

Journal of Digestive Endoscopy

Vishwa M. Dayal¹  Ashish K. Jha¹  Ravikant Kumar¹  Mahesh K. Goenka² 

[1] Department of Gastroenterology, Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India;Institute of GastroSceinces, Apollo Gleneagles Hospital, Kolkata, West Bengal, India;

关键词: novel coronavirus disease 2019;    severe acute respiratory syndrome-coronavirus-2;    world health organization;    hydroxychloroquine;    chloroquine;    remdesivir;    convalescent plasma;    vaccines;   

DOI  :  10.1055/s-0040-1712547

来源: DOAJ

【 摘 要 】

Patients with novel coronavirus disease 2019 (COVID-19) are at significantly increased risk for mortality and morbidity. Current management remains supportive care, ranging from symptomatic outpatient management to full–intensive care support, including intravenous fluids, invasive, and non-invasive oxygen supplementation. In patients with septic shock, treatment with antibiotics and vasopressors are recommended to keep mean arterial pressure (MAP) ≥ 65 mm Hg and lactate < 2 mmol/L. Because of the lack of effectiveness and possible adverse effects, routine corticosteroids should be avoided unless they are indicated for another reason (exacerbation of asthma or chronic obstructive pulmonary disease [COPD], and septic shock in whom fluids and vasopressors do not restore hemodynamic stability). There is currently no sufficient evidence of efficacy of hydroxychloroquine/chloroquine, remdesivir, and other antivirals in the treatment or prevention of COVID-19. Limited evidence shows that COVID-19 convalescent plasma can be used as a treatment of COVID-19 without the occurrence of severe adverse events. Drug regulatory agencies granted an emergency-use authorization of chloroquine/hydroxychloroquine and remdesivir to treat patients when a clinical trial is not available or participation is not feasible. Chloroquine and hydroxychloroquine are associated with QT interval prolongation and life-threatening cardiac arrhythmia in patients with pre-existing cardiovascular disease. Guidelines are issued for use of convalescent plasma in patients with serious or immediately life-threatening COVID-19. Data from several ongoing randomized controlled trials will provide further evidence regarding the safety and efficacy of these drugs for the treatment of COVID-19.

【 授权许可】

Unknown